Kymera Therapeutics vs Recursion Pharmaceuticals
KYMR and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYMR and RXRX compare
Kymera Therapeutics is the larger company, worth 6.9 times as much as Recursion Pharmaceuticals ($10.7B against $1.6B).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −15.1% for Recursion Pharmaceuticals).
Kymera Therapeutics keeps more of each dollar of sales as profit, with a net margin of −342% compared with −946% at Recursion Pharmaceuticals.
Kymera Therapeutics scores higher on the StockData Score (9 against 8 for Recursion Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYMR | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | $10.7B | $1.6B |
| Share price | $125.85 | $2.90 |
| Change, 1 year | 97.8% | −32.9% |
| Change, 5 years | 134% | −84.6% |
| Beta (5Y) | 0.54 | 2.37 |
| Employees | 238 | 50 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 105× | 28.4× (better) |
| P/B | 6.7× | 1.7× (better) |
| FCF yield | −2.7% (better) | −22.7% |
| Fair value | $36.91 | $2.97 |
| Margin of safety | −241% | 2.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 134% (better) | −15.1% |
| Revenue growth, 5Y average | 2.9% | 79.9% (better) |
| Profitability | ||
| Gross margin | 0.00% | 3.5% (better) |
| Operating margin | −396% (better) | −992% |
| Net margin | −342% (better) | −946% |
| FCF margin | −283% (better) | −642% |
| Return on equity | −27.3% (better) | −56.6% |
| Return on invested capital | −59.0% (better) | −109% |
| Financial health | ||
| Debt / equity | 0.00 | 0.02 (better) |
| Interest coverage | – | −367.3× |
| Current ratio | 11.13 (better) | 5.03 |
| Altman Z-score | 41.07 (better) | −0.51 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −24.9% |
| Shareholder yield | 0.00% (better) | −24.9% |
| Ownership | ||
| Held by institutions | 114% | 67.6% |
| Held by insiders | 38.3% | 5.6% |
| Insider net buying, 12 months | −$301M | −$7.4M (better) |
| Short interest, % of float | 16.0% | 28.2% |
Go deeper
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.